Leqvio (Inclisiran) for Familial Hypercholesterolemia: What the Long-Term Follow-Up Data Really Show

What Is Inclisiran, and Why Does FH Matter Differently for Women?

Inclisiran is a small-interfering RNA (siRNA) that targets PCSK9 messenger RNA in hepatocytes, reducing PCSK9 protein synthesis and allowing more LDL receptors to recycle back to the cell surface. The result is a sustained, roughly 50% drop in LDL-C that lasts six months from a single subcutaneous injection. Familial hypercholesterolemia affects approximately 1 in 250 people worldwide, meaning millions of women are living with it, many undiagnosed.

FH is not a gender-neutral condition. Women with untreated heterozygous FH (HeFH) carry a cardiovascular risk roughly 125-fold higher than the general population before menopause, according to a registry analysis, and the absolute risk of coronary heart disease in women with HeFH rises sharply after age 50, coinciding with the estrogen withdrawal of menopause. The perimenopausal estrogen decline itself drives LDL up by 10-15 mg/dL on average, which can tip a woman with borderline-controlled FH into a much higher-risk category. Inclisiran has not been studied specifically in perimenopausal women with FH, and that evidence gap deserves naming plainly.

The FDA-Approved vs. Off-Label Boundary

The FDA approved inclisiran in December 2021 for adults with HeFH or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL lowering on maximally tolerated statins. Use in homozygous FH (HoFH) remains off-label in the United States, though the European Medicines Agency has granted approval in that population. Prescribing inclisiran for HoFH, or as monotherapy without a statin when a statin is not contraindicated, or during pregnancy, falls outside the approved label and requires a documented clinical justification.

This article covers both the approved HeFH indication and the off-label extension into HoFH and other FH contexts where clinicians may use inclisiran based on long-term follow-up evidence.

The ORION Trial Program: A Five-Year Arc

The ORION trials form the evidence spine for inclisiran in FH. Understanding which trials enrolled women, and in what proportion, is essential for interpreting the data you receive from your clinician.

ORION-9: The Key HeFH Trial

ORION-9 enrolled 482 adults with HeFH, randomized to inclisiran 284 mg or placebo at day 1, day 90, and every 180 days thereafter. Women made up 46% of participants. At day 510 (approximately 17 months), inclisiran produced a time-averaged LDL-C reduction of 44.3% versus a 1.8% increase with placebo (p < 0.001). The absolute LDL-C reduction from baseline was 67.7 mg/dL in the inclisiran arm.

Injection-site reactions occurred in 2.6% of the inclisiran group versus 0.9% of placebo, and no serious injection-site adverse events were reported. Liver enzyme elevations and renal function changes were comparable between arms. Women-specific subgroup data from ORION-9 were not published separately, which is a meaningful evidence gap given that female sex affects hepatic PCSK9 expression and LDL receptor activity.

ORION-1 Open-Label Extension: The Longest Dataset

The ORION-1 dose-finding trial (n = 501) fed into an open-label extension that has now generated five-year follow-up data published in 2024. Across five years of twice-yearly dosing, LDL-C reductions were sustained in the range of 45-52% from baseline, with no evidence of tachyphylaxis or antibody-mediated drug resistance. The safety profile did not change materially from the parent trial: injection-site reactions remained the predominant treatment-emergent adverse event, and no new hepatic or renal signals emerged.

Women comprised approximately 36% of the ORION-1 extension population. The authors did not perform a sex-stratified efficacy analysis in the five-year report, which means the durability data are largely extrapolated to women rather than directly studied in them. You should know this when your clinician quotes the five-year figure.

ORION-5: Off-Label HoFH Territory

ORION-5 enrolled 56 patients with HoFH, the most severe form of FH, where LDL receptors are virtually absent. In this population, inclisiran reduced LDL-C by a time-averaged 22.3% at day 510, substantially less than in HeFH, because the drug's mechanism depends on upregulating LDL receptor activity. Women comprised 41% of the ORION-5 cohort. The modest but statistically significant effect in HoFH is the rationale for off-label prescribing in that population, particularly for patients who cannot tolerate lomitapide or who decline lipoprotein apheresis.

VICTORION-2P: The Cardiovascular Outcomes Signal

VICTORION-2P, a randomized trial of 15,828 patients with established ASCVD and LDL >70 mg/dL on maximally tolerated statins, reported a 15.8% relative risk reduction in major adverse cardiovascular events (MACE) with inclisiran versus placebo at a median follow-up of 40 months. Women made up 25% of the trial, a proportion that mirrors the longstanding underrepresentation of women in cardiovascular outcome trials. The female-specific MACE reduction was directionally consistent but did not reach statistical significance as a subgroup, because the trial was not powered for sex-stratified outcomes.

Sex-Specific Pharmacology: What the Biology Tells Us

Women have higher baseline PCSK9 plasma levels than men at most life stages, a difference driven partly by estrogen's upregulation of hepatic PCSK9 expression. Estradiol increases PCSK9 transcription, which is one reason premenopausal women tend to have lower LDL than men of the same age despite higher PCSK9 levels, because circulating estrogen simultaneously upregulates LDL receptors more than it upregulates PCSK9 net clearance.

After menopause, estrogen withdrawal lowers LDL receptor expression more than it lowers PCSK9, so LDL rises. This means a postmenopausal woman with HeFH faces a compounding effect: the genetic LDL receptor deficit plus the acquired receptor loss from estrogen withdrawal. Inclisiran's mechanism, suppressing PCSK9 to rescue whatever residual LDL receptor function remains, should theoretically confer benefit in postmenopausal HeFH, but no trial has been designed to test this directly.

Body weight and body composition also affect inclisiran pharmacokinetics. Because inclisiran is delivered subcutaneously and distributed primarily to the liver via GalNAc targeting, renal function matters more than body mass for dosing adjustments. The prescribing information does not recommend dose adjustment for obesity, but women with PCOS, who often carry both elevated PCSK9 and insulin resistance, represent a clinically understudied group who might particularly benefit from PCSK9 suppression.

Long-Term Safety: What Five Years of Data Look Like

Injection-Site Reactions

Across ORION-1 through ORION-9 and the extension cohort, injection-site reactions are the single most consistent signal. They are almost universally mild to moderate, self-limiting, and do not appear to increase in frequency with prolonged exposure. No anaphylaxis has been attributed to inclisiran in the trial dataset.

Liver and Kidney

Inclisiran is cleared renally as intact drug and metabolic fragments. In patients with severe renal impairment (eGFR 15-29 mL/min/1.73 m²), no dose adjustment is required per the label, though exposure is modestly increased. Dialysis patients were excluded from trials. Women with lupus nephritis or chronic kidney disease secondary to autoimmune conditions, which disproportionately affect women, may reach this threshold earlier than the general FH population, and this pharmacokinetic nuance warrants monitoring.

Alanine aminotransferase (ALT) elevations above three times the upper limit of normal occurred in <1% of inclisiran-treated patients across ORION trials and were not statistically different from placebo.

Muscle and Cognitive Effects

PCSK9 inhibitors as a class raised early concerns about myopathy and cognitive effects based on Mendelian randomization signals. Across five years of ORION data, no excess myopathy or neurocognitive adverse events were attributed to inclisiran. This is reassuring for women who often discontinue statins due to statin-associated muscle symptoms (SAMS), a side effect that occurs more frequently in women than men.

Hormonal and Menstrual Effects

No trial in the ORION program collected menstrual cycle data, ovarian function markers, or sex hormone levels as outcomes. Given that cholesterol is the biosynthetic precursor to all steroid hormones, including estrogen and progesterone, the theoretical concern about very aggressive LDL lowering disrupting hormonal synthesis exists. At achieved LDL-C levels of 30-70 mg/dL seen in ORION participants, there is no clinical signal of adrenal or gonadal insufficiency, but this has not been formally assessed in women of reproductive age in any inclisiran trial. This is a genuine evidence gap.

A practical framework for monitoring women on long-term inclisiran: check fasting lipid panel and ALT at 3 months after initiation, then annually. For women of reproductive age, confirm contraception status at every biannual injection visit. For perimenopausal women, consider checking LDL-C at both the trough (just before the next injection) and peak (one month post-injection) to capture the full range, since the perimenopausal LDL rise may erode trough efficacy over time.

Pregnancy, Lactation, and Contraception: A Required Discussion

Inclisiran is contraindicated in pregnancy. This is not a precautionary soft warning. The FDA label carries a contraindication based on findings from animal reproductive toxicity studies showing fetal harm at exposures below the human clinical dose.

Animal Reproductive Data

In rat studies, inclisiran administered subcutaneously at doses producing systemic exposures approximately 6-fold the human area-under-the-curve caused increased post-implantation loss and reduced fetal body weight. No adequate and well-controlled human pregnancy studies exist. The FDA pregnancy category system has been replaced by the PLLR narrative labeling, and inclisiran's label states it should not be used in pregnancy and that the drug may cause fetal harm.

Human Pregnancy Data

As of the label date and available literature, no prospective human pregnancy outcome data exist for inclisiran. Given the twice-yearly dosing schedule, a woman who conceives shortly after an injection will carry drug exposure through at least part of the first trimester before the exposure substantially clears. The half-life of inclisiran after subcutaneous injection is approximately 9 hours for the circulating drug, but the hepatic siRNA effect persists for months because the intracellular RISC complex loaded with the guide strand is long-lived. This means stopping injections does not immediately remove the pharmacodynamic effect.

If you are trying to conceive, inclisiran should be discontinued well in advance of a planned pregnancy, and transition to a pregnancy-compatible lipid-lowering strategy (typically bile acid sequestrants, which are not systemically absorbed) should be arranged with your clinician before stopping contraception.

Lactation

No data exist on the presence of inclisiran or its metabolites in human breast milk, effects on the breastfed infant, or effects on milk production. Because of the potential for adverse effects in a nursing infant and because the drug is not immediately reversible, inclisiran should not be used during breastfeeding. Postpartum women with HeFH who are breastfeeding can discuss timing of reinitiation with their clinician after weaning is complete.

Contraception Requirements

Because inclisiran's pharmacodynamic effect persists for approximately six months per injection, the FDA label advises women of reproductive potential to use effective contraception during treatment and for a period following the last dose. The label does not specify a precise washout duration for contraceptive purposes, and individual clinicians vary in their guidance. A reasonable clinical approach, based on the pharmacodynamic persistence, is to maintain effective contraception for at least 12 months after the last injection.

Effective contraception options for women on inclisiran include combined oral contraceptives, intrauterine devices (hormonal or copper), etonogestrel implant, and depot medroxyprogesterone acetate. There are no known pharmacokinetic interactions between inclisiran and hormonal contraceptives, because inclisiran is not metabolized by CYP enzymes and does not induce or inhibit them.

Who This Is Right For, and Who Should Pause

Women Who Are Good Candidates

You are likely a reasonable candidate for inclisiran if you:

• Have confirmed HeFH (Dutch Lipid Clinic Network score >8, or genetic confirmation of a pathogenic LDLR, APOB, or PCSK9 variant) and LDL-C remains above goal on maximally tolerated statin plus ezetimibe
• Are postmenopausal and have seen a post-menopause LDL spike that has pushed your cardiovascular risk into the high or very-high category
• Cannot tolerate biweekly or monthly subcutaneous injections (evolocumab, alirocumab) and prefer a twice-yearly schedule
• Have statin-associated muscle symptoms that led to statin dose reduction, leaving LDL inadequately controlled
• Have HoFH and are not candidates for or have not achieved adequate LDL control with lomitapide plus apheresis (off-label use)

Women Who Should Not Use Inclisiran Now

You should not use inclisiran if you:

• Are pregnant or planning pregnancy within the next 12 months
• Are currently breastfeeding
• Have active liver disease with significantly elevated transaminases (ALT >3x ULN at baseline)
• Are <18 years old (not studied in pediatric FH)

Life-Stage Nuances

Reproductive years (18-40): Contraception counseling is mandatory before the first injection. For women with HeFH who have good LDL control on statin plus ezetimibe and are planning pregnancy, it may be reasonable to defer inclisiran until after the family-building phase, then initiate at the postpartum or post-weaning visit.

Perimenopause (40-55): The menopause transition unmasks LDL elevations. This is often the time when FH is first diagnosed in women, because LDL crosses a threshold that triggers lipid panel ordering. Inclisiran may be particularly useful here, but hormonal variability during perimenopause may affect LDL-C response variability. No trial has stratified outcomes by menopausal status.

Postmenopause (55+): The highest absolute cardiovascular risk period for women with FH. This group likely derives the most absolute benefit from LDL lowering. The ORION-9 mean age was 56 years, meaning postmenopausal women were the modal participant.

PCOS: Women with PCOS carry elevated PCSK9 levels, insulin resistance, and often dyslipidemia, but clinical trials of inclisiran have not enrolled a PCOS-enriched cohort. Whether inclisiran's effect on LDL-C in PCOS differs from the general HeFH population is unknown.

Practical Dosing and Administration for Women

The standard inclisiran dosing schedule is:

• Day 1: 284 mg subcutaneous injection (administered in a clinic setting)
• Day 90 (3 months): 284 mg subcutaneous injection
• Every 6 months thereafter: 284 mg subcutaneous injection

The injection is given in the abdomen, upper arm, or thigh. Rotating sites reduces cumulative local reaction risk. For women who experience injection-site discomfort, warming the pre-filled syringe to room temperature for 30 minutes before injection and applying a cold compress afterward reduces local pain.

No renal dose adjustment is required for eGFR above 15 mL/min/1.73 m². For women with severe hepatic impairment (Child-Pugh C), inclisiran has not been studied and should be avoided.

Because inclisiran is not metabolized via CYP3A4 or any other major CYP pathway, it does not interact with tamoxifen, aromatase inhibitors, hormonal contraceptives, menopausal hormone therapy, or thyroid replacement, all of which are common co-medications in women with FH.

Interpreting Your Lab Results Over Time

LDL-C typically falls 50-60% within four weeks of the first injection, reaches nadir at approximately eight weeks, then gradually rises toward the six-month trough before the next injection. The time-averaged LDL-C, not the nadir, is the clinically relevant efficacy metric and the figure reported in ORION trials.

If your LDL-C at the pre-injection trough is only modestly reduced (say, <30% from baseline), consider:

1. Adherence to the injection schedule (missing an injection by more than two weeks disrupts the loading pattern)
2. Whether ezetimibe has been co-prescribed, since combination therapy produces additive LDL lowering
3. Thyroid function: hypothyroidism elevates LDL-C and is more common in women with FH than in the general population; an untreated TSH above 10 mIU/L will blunt any lipid-lowering intervention
4. Perimenopausal LDL fluctuation, which may cause apparent loss of efficacy that stabilizes after menopause

A 2024 analysis of the ORION extension cohort noted that approximately 8% of participants did not achieve the <70 mg/dL LDL-C target on inclisiran plus statin, consistent with the heterogeneity of FH genetic backgrounds and baseline LDL burden. For these patients, adding ezetimibe or considering lipoprotein apheresis are the next steps, not increasing inclisiran dose.

The Cost and Access Reality

Inclisiran's list price in the United States is approximately $3,500 per injection, or $7,000 annually for maintenance dosing. The twice-yearly schedule is an access advantage over monthly PCSK9 monoclonal antibodies for women who struggle to self-inject or who face transportation barriers to monthly clinic visits. Novartis patient-assistance programs and specialty pharmacy prior-authorization pathways exist, but approval rates for HeFH indications vary by payer.

For off-label HoFH use, prior authorization almost universally requires documentation of genetic confirmation of HoFH, failure of maximally tolerated statin plus ezetimibe, and often a trial of evolocumab or alirocumab first. Women's-health clinicians managing FH should be prepared to write detailed letters of medical necessity that explicitly address the HoFH designation.